Core Insights - The article provides an overview of the latest fund net asset values, highlighting the top-performing and bottom-performing funds in the market [1] Fund Performance Summary Top 10 Funds by Net Value Growth - The top 10 funds with the highest net value growth include: 1. E Fund S&P Biotechnology RMB C: 1.5967, growth of 3.31% 2. E Fund S&P Biotechnology RMB A: 1.6184, growth of 3.31% 3. E Fund S&P Biotechnology USD A: 0.2284, growth of 3.30% 4. E Fund S&P Biotechnology USD C: 0.2253, growth of 3.30% 5. Vanguard Growth A: 1.0911, growth of 2.95% 6. Shenwan Hongyuan Medical A: 0.4952, growth of 2.95% 7. Vanguard Growth C: 1.1104, growth of 2.95% 8. Shenwan Hongyuan Medical C: 0.4867, growth of 2.94% 9. Fuguo Medical Innovation A: 1.8086, growth of 2.86% 10. Fuguo Medical Innovation C: 1.7890, growth of 2.86% [2] Bottom 10 Funds by Net Value Decline - The bottom 10 funds with the largest net value decline include: 1. Dongcai Value Start C: 0.8164, decline of 5.32% 2. Dongcai Value Start A: 0.8302, decline of 5.31% 3. HSBC Jintrust Low Carbon Pioneer A: 3.0533, decline of 4.87% 4. HSBC Jintrust Low Carbon Pioneer C: 2.9915, decline of 4.87% 5. HSBC Jintrust Research Selected Mixed: 1.0754, decline of 4.86% 6. HSBC Jintrust Core Growth A: 1.0195, decline of 4.70% 7. HSBC Jintrust Core Growth C: 0.9970, decline of 4.69% 8. Ping An Research Selected Mixed C: 0.8939, decline of 4.65% 9. Ping An Research Selected Mixed A: 0.9228, decline of 4.64% 10. HSBC Jintrust Intelligent Manufacturing Pioneer C: 2.8535, decline of 4.63% [3] Market Overview - The Shanghai Composite Index opened lower but rebounded, closing slightly down, with a trading volume of 1.96 trillion yuan and a stock performance ratio of 1758 gainers to 3563 losers [5] - Leading sectors include insurance, oil, banking, textiles, and household appliances, while the concept of immunotherapy saw a rise of over 2% [6] - Declining sectors include mineral products and electrical equipment, both dropping over 2% [7] Fund Holdings Analysis E Fund S&P Biotechnology Holdings - The fund's top holdings include: 1. CRISPR Therapeutics AG: 2.14% 2. Exelixis Inc: 1.89% 3. AbbVie Inc: 1.89% 4. Madrigal Pharmaceuticals Inc: 1.84% 5. Moderna Inc: 1.83% - The fund has a concentration of 18.47% in its top ten holdings, focusing on the pharmaceutical sector, and has outperformed the market [8] Dongcai Value Start Holdings - The fund's top holdings include: 1. Longi Green Energy: -7.35% 2. Foster: -6.08% 3. Zhongyou Technology: -2.11% 4. Yinke Co.: -0.74% 5. Xinyi Solar: -4.27% - The fund has a concentration of 47.27% in its top ten holdings, focusing on the renewable energy sector, and has underperformed the market [8]

Group 1 - The core viewpoint of the news is that Haishi Ke (002653.SZ) has reported an increase in institutional holdings, indicating growing investor interest [1] - As of October 28, 2025, 42 institutional investors hold a total of 122 million shares of Haishi Ke, representing 10.92% of the total share capital [1] - The top ten institutional investors collectively hold 8.86% of the shares, with a 0.41 percentage point increase compared to the previous quarter [1] Group 2 - In the public fund sector, 21 funds increased their holdings, with a total increase ratio of 0.60% [2] - Conversely, 14 funds reduced their holdings, with a total decrease ratio of 0.75% [2] - Six new public funds were disclosed during this period, while 240 funds were not disclosed compared to the previous quarter [2]

Core Insights - In the first three quarters of this year, 98% of the 976 comparable ordinary equity funds achieved positive performance, with only 23 funds experiencing declines [1] Group 1: Top Performing Funds - The top four performing ordinary equity funds, namely Huaan Pharmaceutical Biotechnology Stock A, Huaan Pharmaceutical Biotechnology Stock C, E Fund Information Industry Select Stock A, and E Fund Information Industry Select Stock C, all saw their performance double, with increases of 103.31%, 102.65%, 102.03%, and 101.26% respectively [1] - Huaan Pharmaceutical Biotechnology Stock's second-quarter report indicates heavy investments in companies such as Innovent Biologics, CSPC Pharmaceutical Group, and others, with significant stock price increases, particularly for 3SBio, which surged over four times [1] - E Fund Information Industry Select Stock's top ten holdings are primarily in the semiconductor sector, including companies like NewEase, Huitian Technology, and Tencent Holdings [1] Group 2: Fund Management and Performance - The E Fund Information Industry Select Stock is managed by Zheng Xi, who has extensive experience in equity investment management and has held various roles within E Fund [2] - Other notable funds such as E Fund Strategic Emerging Industries Stock A and C, and Jiashi Mutual Selection Stock A and C, also reported over 90% increases in the first three quarters [2] - Jiashi Mutual Selection Stock focuses on pharmaceutical stocks, with major holdings in companies like Innovent Biologics and Hengrui Medicine, managed by Hao Miao, who has a strong background in biomedical research [2] Group 3: Underperforming Funds - The fund with the largest decline, Minsheng Jianyin Preferred Stock, fell by 7.39%, primarily investing in blue-chip consumer stocks [4] - The fund's top ten holdings include companies like CATL and BYD, with the current manager, Liu Hao, having less than a year of experience [4] - Other underperforming funds include Changxin Consumer Select Quantitative Stock and Qianhai Kaiyuan Traditional Chinese Medicine Stock, both down by over 5% [4]

Core Insights - Despite the active performance of sectors like technology, new consumption, and pharmaceuticals, investors have found it challenging to achieve ideal returns, with the CSI 300 index showing a mere 0.03% increase year-to-date as of June, contrasting sharply with the nearly 8% rise in the Wind Active Equity Mixed Fund Index, highlighting the scarcity of professional research capabilities in volatile markets [1] Group 1: Fund Performance - In Q2, public funds achieved a total profit of 386.3 billion yuan, with Fuqun Fund ranking fifth in the industry with a profit of 19.492 billion yuan. For the first half of the year, Fuqun Fund generated 29.832 billion yuan for investors, placing it fourth overall [2] - Fuqun Fund's active equity research strength is a core competitive advantage, with 11 of its equity funds ranking in the top 10 of their categories over the past year. Notably, Fuqun Medical Innovation Stock A and Fuqun Active Growth One-Year Regular Open Mixed Fund both exceeded 40% in returns [2][3] Group 2: Long-term Performance - Over the past five and seven years, Fuqun Fund has had 5 and 10 products, respectively, ranking in the top 10 of their categories. Fuqun New Vitality Flexible Allocation Mixed A achieved returns of 67.84% and 175.32% over the past five and seven years, respectively, ranking first in its category [4] - Fuqun Global Consumer Selection A, managed by a Hong Kong fund manager, has shown impressive long-term performance with returns of 86.16% and 70.68% over the past two and three years [3] Group 3: Fixed Income and Quantitative Strategies - In the fixed income sector, Fuqun Fund's products have maintained a "steady" approach despite market challenges. Fuqun Strong Return Regular Open Bond A achieved returns of 13.03%, 23.28%, and 45.09% over three, five, and seven years, respectively, ranking in the top 9% of its category [5] - Fuqun Fund's quantitative strategies have also performed well, with 10 of its quantitative funds ranking in the top 10 of their categories over the past year. The classic broad-based ETF, the Shanghai Composite Index ETF, has consistently ranked in the top 5 over three, five, and seven years [6]

Group 1 - The core viewpoint of the report indicates that the construction materials and coal industries performed well during the period, with the Shanghai Composite Index rising by 1.67% and the Shenzhen Component Index increasing by 2.33% [2][9] - In the recent 12 periods, the comprehensive and pharmaceutical industries showed strong performance, suggesting potential investment opportunities in these sectors [9] - Active equity funds focusing on electronics and coal industries also demonstrated superior performance during this period [14] Group 2 - Among various fund types, actively managed stock funds increased by 1.55%, while mixed funds rose by 1.63%, and bond funds saw a slight decline of 0.16% [2] - The average return of convertible bond funds was notably high at 12.46% year-to-date, indicating a strong performance in this category [17] - QDII funds, particularly those focused on Asia-Pacific and emerging markets, led the performance with an increase of 2.56% during the period [19][21]

Core Viewpoint - The article emphasizes the continuous improvement and advancement of the investment research system at Fuqun Fund, highlighting its strong performance in equity investment and the growing demand for stable mid-to-long-term investment products in the Chinese market [1][4][6]. Group 1: Market Context - As Chinese residents' wealth continues to grow, the demand for asset allocation is increasing, making public funds an important part of investment choices [3]. - Investors are increasingly focused on long-term performance rather than just short-term results, leading to a more rigorous evaluation of fund performance [3]. Group 2: Fuqun Fund's Performance - Fuqun Fund's active equity funds have demonstrated excellent investment capabilities, with a 20-year return of 953.86%, ranking 4th in the industry [6]. - As of June 30, 2025, 11 of Fuqun Fund's equity funds ranked in the top 10 of their categories for the past year, with several funds achieving returns exceeding 40% [8]. Group 3: Specific Fund Highlights - Fuqun Medical Innovation Stock A achieved a return of 58.87% over the past year, ranking 2nd among 45 funds in the medical and healthcare sector [8]. - Fuqun Consumption Select 30 Stock A has performed well in the new consumption investment trend, ranking 2nd among 38 funds in the consumption sector over the past year [8]. Group 4: Fixed Income and Hybrid Products - Fuqun Fund's fixed income products have shown strong performance, with Fuqun Strong Return Bond A achieving returns of 13.03%, 23.28%, and 45.09% over the past three, five, and seven years, respectively, ranking in the top 9 of its category [10]. - The "fixed income + equity" products, such as Fuqun Enhanced Bond and Fuqun Jiuli Stable Allocation Mixed A, have also performed well, with returns of 28.74% and 41.24% over the past year, ranking first in their categories [11]. Group 5: Quantitative Investment - Fuqun Fund's quantitative products have consistently ranked well, with 10 quantitative funds placing in the top 10 of their categories over the past year [12]. - The classic ETF, Fuqun Shanghai Composite Index ETF, has also performed well, ranking among the top five in its category over the past three, five, and seven years [12].